Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim,

Where Does Boehringer Ingelheim Stand Between Oral or Injectable GLP-1’s Being The Future of Obesity Care?

ByNicholas Jacobus,Brian Hilberdink

June 17th 2026

How Behavioral and Engagement Insights Improve Persistence in Patient Support Programs

ByIsabelle Amick,Jack McFeely

June 17th 2026

The Industry's Interest in Vaccine Platforms

ByMike Hollan,Silvia Taylor

June 17th 2026

Solving Data Problems with Casual Human Biology: Q&A with Dr. Brent Richards

ByMike Hollan,Brent Richards, MD, MSc

June 17th 2026

Pharmaceutical Executive Daily: FDA has Approved Skinvive by Juvéderm

ByNicholas Jacobus

June 16th 2026

Pharmaceutical Executive, October 2017 Issue (PDF)

Articles in this issue

Related Content

Where Does Boehringer Ingelheim Stand Between Oral or Injectable GLP-1’s Being The Future of Obesity Care?

How Behavioral and Engagement Insights Improve Persistence in Patient Support Programs

The Industry's Interest in Vaccine Platforms

Solving Data Problems with Casual Human Biology: Q&A with Dr. Brent Richards

Pharmaceutical Executive Daily: FDA has Approved Skinvive by Juvéderm

Trending on PharmExec

Elicio Therapeutics’ Shares Drop Following Announcement of Phase II Trial Results

Novavax's Strategy Across Commercial, R&D, and Partnerships

Partnering in Non-Opioids: Q&A with Dr. Edward Littler and Dave Watson

FDA Approves Skinvive by Juvéderm for Improvement of Neck Appearance

Pharmaceutical Executive Daily: FDA has Approved Skinvive by Juvéderm